Stock Watch: The Meaning Of Biosimilar Success
Big Pharma, Generic Or Biotech Firms: Which Will Be The Long-Term Winners?
With two recent divestments of biosimilar franchises and lackluster performances from smaller biosimilar biotechs, the sector needs some standard-bearing successes.
You may also be interested in...
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead
After confirming rumors that it would offload its biosimilars unit to its long-term partner Biocon, Viatris has outlined plans to add to the expected cash proceeds with other divestments to complete on several strategic goals up to 2023. Bumping up R&D spending to facilitate complex generic launches is a continued priority for the company.
The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.